ClinicalTrials.gg
RecruitingNCT06514508Updated Sep 14, 2026

Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma Patients

A Phase 3 interventional study of Motixafortide+G-CSF and Placebo+G-CSF in Multiple Myeloma, sponsored by Guangzhou Gloria Biosciences Co., Ltd.. Recruiting at 2 sites in China. Open to participants aged 18 Years to 78 Years. Per ClinicalTrials.gov, last updated 2026-09-14.

Sponsored by Guangzhou Gloria Biosciences Co., Ltd. · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 78 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 28 studies testing Granulocyte Colony-Stimulating Factor in Multiple Myeloma — 1 open to participants now, 1 under way, 1 of them phase 3. Granulocyte Colony-Stimulating Factor · Multiple Myeloma.

Planned enrollment
9th of 28
60 · median 38
Started
2025
the only one that year
Phase 3
2 of 28
1 open now
Registered
27th of 28
by date

Among the 28 studies testing Granulocyte Colony-Stimulating Factor in Multiple Myeloma, this one is the 9th largest by planned enrollment, is the only one that started in 2025, is one of 2 in phase 3, and was the 27th registered.

Multiple Myeloma

3,764 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

1 of the 28 studies testing Granulocyte Colony-Stimulating Factor in Multiple Myeloma is open now, in 1 country.

By country, each count listing its studies:

About Granulocyte Colony-Stimulating Factor

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 583 Multiple Myeloma studies recruiting now, 428 (73%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 78 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing Granulocyte Colony-Stimulating Factor in Multiple Myeloma, or all of them as a file.
02

Study summary

This is a randomized, double-blinded, placebo-controlled, multi-center phase Ⅲ bridging clinical study designed to evaluate the efficacy, safety, and pharmacokinetic and pharmacodynamic profiles of Motixafortide (BL-8040) + G-CSF vs placebo + G-CSF mobilized hematopoietic stem cells for autologous transplantation in Chinese patients with multiple myeloma.

03

Conditions studied

  • Multiple Myeloma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 78 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (Limit: 15,000 characters)

    1. Patients must have a signed study prior to entering the study.
    2. Patients must be between the ages of 18 and 78 years.
    3. Diagnosis of active multiple myeloma (aMM) as defined by IMWG criteria.
    4. At least one week (7 days) from last induction cycle of combination/multi-agent chemotherapy (e.g. KRD [carfilzomib, lenalidomide, dexamethasone] or VRD [bortezomib, lenalidomide, dexamethasone]) or from last single agent chemotherapy (e.g. lenalidomide, pomalidomide, bortezomib, dexamethasone, etc) prior to the first dose of G-CSF for mobilization.
    5. Eligible for Hematopoietic stem cell transplantation according to the Investigator's discretion.
    6. The subjects should be in first or second CR (including CR and SCR) or PR (including PR and VGPR).
    7. (ECOG) performance status 0 or 1.
    8. Adequate organ function at screening.
    9. Female subjects must be of non- or, if of childbearing potential, must have a negative serum pregnancy test at screening and negative serum pregnancy test within 72 hours prior to G-CSF first administration. Women of childbearing potential (WOCBP) and male subjects with WOCBP partners must agree to use highly effective method during the study period and within 90 days after the last study treatment.

Exclusion criteria

Exclusion Criteria:

  1. Previous history of or allogeneic-HCT.
  2. Failed previous HSC collections or collection attempts.
  3. Taken any of the listed below concomitant medications, growth factors or stimulating agents within the designated :

    1. Dexamethasone: 7 days
    2. Thalidomide: 7 days
    3. Lenalidomide: 7 days
    4. Pamolidomide: 7 days
    5. Bortezomib: 7 days
    6. Carfilzomib: 7 days
    7. G-CSF: 14 days
    8. GM-CSF or Neulasta®: 21 days
    9. Erythropoietin or erythrocyte stimulating agents: 30 days
    10. Eltrombopag, romiplostim or stimulating agents: 30 days
    11. Carmustine (BCNU): 42 days/6 weeks
    12. Daratumumab or any other anti-CD38: 28 days
    13. Ixazomib: 7 day.
  4. Received >6 cycles lifetime exposure to thalidomide or lenalidomide.
  5. Received >8 cycles of alkylating agent combinations.
  6. Received > 6 cycles of melphalan.
  7. Received prior treatment with radioimmunotherapy (e.g. radionuclides).
  8. Received prior treatment with venetoclax.
  9. Plans to receive maintenance treatment within 60 days post- transplantation (e.g.lenalidomide, bortezomib, pomalidomide, thalidomide, carfilzomib, etc.).
  10. Has received a within 30 days of the planned start of G-CSF administration. Seasonal flu vaccines that do not contain live virus are permitted.
  11. Known active or carcinomatous meningitis.
  12. A history of allergic reactions attributed to compounds of similar chemical or biologic composition to motixafortide, G-CSF, or other agents used in the study.
  13. Has an active or uncontrolled infection requiring systemic therapy.
  14. Has a known additional that is progressing or requires active treatment.
  15. Is currently participating and/or receiving study therapy or has participated in a study of an agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment.
  16. O2 saturation \< 92% (on room air).
  17. Personal history or family history of Long Syndrome or Torsade de Pointes.
  18. History of unexplained syncope, syncope from an uncorrected cardiac etiology, or family history of sudden cardiac death.
  19. Myocardial infarction, CABG, coronary or cerebral artery stenting and/or angioplasty, stroke, cardiac surgery, or hospitalization for congestive heart failure within 3 months, Angina Pectoris Class >2 or Heart Failure Class >2.
  20. at screening showing QTcF > 470 msec and/or PR > 280 msec.
  21. Mobitz II 2nd degree AV Block, 2:1 AV Block, High Grade AV Block, or Complete Heart Block, unless the patient has an implanted pacemaker or implantable cardiac defibrillator (ICD) with backup pacing capabilities.
  22. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
  23. Is pregnant or breast feeding or expecting to conceive or women of unless consent to use two methods or highly effective contraception, within the projected duration of the trial, starting with the Screening Visit through 90 days after the last dose of study drug.
  24. Known (HIV) or active (e.g., Hepatitis B Surface Antigen [HBsAg] reactive and HBV DNA>500 IU/mL or >2500 copies/mL) or (e.g., Hepatitis C Virus [HCV] RNA [qualitative] is positive).
  25. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating Investigator.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Motixafortide+G-CSF

    Drug: Motixafortide+G-CSF

  • Placebo comparator
    Placebo+G-CSF

    Drug: Placebo+G-CSF

Interventions

  • DrugMotixafortide+G-CSF

    Drug pages: MotixafortideStudies of MotixafortideMotixafortide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · Granulocyte Colony-Stimulating FactorStudies of Granulocyte Colony-Stimulating FactorGranulocyte Colony-Stimulating Factor pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients will receive the first dose of motixafortide (1.25 mg/kg) by subcutaneous (SC) injection on the evening of Day 4 (10 to 14 hours) prior to initiation of the first apheresis. A second dose of motixafortide can be administered 10 to 14 hours before a third apheresis, if necessary for patients who did not reach the goal of collection. Injections of G-CSF per standard of care.

    Also known as: BL-8040+G-CSF

  • DrugPlacebo+G-CSF

    Patients will receive the first dose of placebo by subcutaneous (SC) injection on the evening of Day 4 (10 to 14 hours) prior to initiation of the first apheresis. A second dose of placebo can be administered 10 to 14 hours before a third apheresis, if necessary for patients who did not reach the goal of collection. Injections of G-CSF per standard of care.

06

What researchers measure

Primary outcomes

  1. Proportion of patients mobilizing ≥6.0 × 10^6 CD34+ cells/kg with up to 2 apheresis sessions

    Time frame: Up to day 6

Secondary outcomes

  1. Proportion of patients who collect ≥2.0 × 10^6 CD34+ cells/kg in 1 apheresis session

    Time frame: Up to Day 5

  2. Proportion of patients who collect ≥6.0 × 10^6 CD34+ cells/kg in 1 apheresis session

    Time frame: Up to Day 5

  3. Number of CD34+ cells/kg collected

    Time frame: Up to Day 8

  4. Maximum plasma concentration (Cmax)

    Time frame: Up to Day 8

  5. Time from transplantation to neutrophil engraftment

    Time frame: Up to post transplantation Day 29

  6. Time from transplantation to platelets engraftment

    Time frame: Up to post transplantation Day 29

  7. Graft durability at 100 days post-transplantation

    Graft durability is defined as maintenance of at least 2 of the following 3 criteria: * Platelet count ≥50 × 10\^9/L without transfusion for at least 2 weeks. * Hemoglobin level ≥10 g/dL with no erythropoietin support or transfusions for at least 1 month. * Absolute neutrophil count (ANC) ≥1.0 × 10\^9/L for 1 week.

    Time frame: Up to post transplantation Day 100

  8. Change from Baseline in peripheral blood CD34+ cell concentration

    Time frame: Up to Day 8

  9. Incidence of adverse events (AEs) and serious adverse events (SAEs)

    Time frame: Up to Day 38

07

Study locations

1 of 2 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2025 to primary completion in Sep 2026, 9 months.

Of 109 industry-sponsored phase 3 interventional studies under Multiple Myeloma, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 66. This study's 9 months is below that.

Counting every sponsor, half of 181 studies reached it within 55 months; a quarter within 34 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 10, 2024
First posted
Jul 23, 2024
StartActual
Dec 1, 2025
Primary completionActual
Sep 11, 2026
CompletionEst.
May 31, 2027
Last update
Sep 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06514508
Lead sponsor
Guangzhou Gloria Biosciences Co., Ltd.
Responsible party
Sponsor
First posted
Jul 23, 2024
Start date
Dec 1, 2025
Primary completion
Sep 11, 2026
Completion
May 31, 2027 (estimated)
Last update
Sep 14, 2026

Study contacts

Xiaojun Huang, M.D.
Contact
xjhrm@medmail.com.cn
+86-13701389625
Jun Ma, M.D.
Contact
majun0322@126.com
+86-0451-84883471

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Motixafortide · Granulocyte Colony-Stimulating Factor

Start the discussion